Johnson & Johnson (NYSE:JNJ) Shares Purchased by Gilman Hill Asset Management LLC

by · The Cerbat Gem

Gilman Hill Asset Management LLC raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 18.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,341 shares of the company’s stock after buying an additional 2,195 shares during the period. Gilman Hill Asset Management LLC’s holdings in Johnson & Johnson were worth $2,324,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Innealta Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $27,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at $43,000. Fairfield Financial Advisors LTD purchased a new position in Johnson & Johnson in the 2nd quarter valued at $46,000. Grayhawk Investment Strategies Inc. boosted its stake in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the last quarter. Finally, Fairway Wealth LLC raised its position in shares of Johnson & Johnson by 217.1% in the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after buying an additional 228 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. TD Securities lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.31.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 0.6 %

JNJ traded up $0.95 during mid-day trading on Friday, hitting $161.46. 5,253,459 shares of the stock were exchanged, compared to its average volume of 7,039,524. The firm’s fifty day moving average is $162.59 and its two-hundred day moving average is $154.48. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $388.58 billion, a PE ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the firm posted $2.80 earnings per share. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.07%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).